Antibiotic Effectiveness For Cystic Fibrosis May Be Influenced By PH, Oxygen

| October 17, 2018

article image
People living with cystic fibrosis spend their lives battling chronic lung infections resistant to antibiotic therapy. A one-size-fits all approach to wiping out the bacterium may not be the best approach for all patients with the disease, according to a new study led by Pieter Dorrestein, a professor at the University of California San Diego, and Robert Quinn, a Michigan State University researcher who conducted the research at UC San Diego.

Spotlight

BioTech Annecto

BioTech Annecto is a social networking organization, whose aim is to bring together entrepreneurs, investors, scientists, attorneys, journalists and other professionals in the biotechnology sector: pharmaceutical, healthcare and biomedical, cosmetics, and environment. Launched February 2009 in Montreal (Quebec, Canada), BioTech Annecto (previously known as BioTech Montreal) is inviting people, one Tuesday every month, from the Montreal biotechnology community to meet at trendy locations around town. Members come from the business world, from public agencies as well as academic institutions. This allows regular communication and exchanges between industry, the public sector and academia.

OTHER ARTICLES

Defense biotech research looks to eliminate bacteria causing traveler’s diarrhea, reduce jet lag duration

Article | April 9, 2020

World traveler‘s will rejoice at the idea of a seemingly magical device that would guarantee they never suffer from the all-too-familiar stomach issues that come from traveling internationally while reducing jet lag at the same time. But it’s not just privileged globetrotters that would benefit from a device that eliminates the bacteria associated with the so-called Montezuma’s Revenge. In 2016, more than 230,000 children around the world died from some of the same types of bacteria as those that cause traveler’s diarrhea, and the bacteria mainly come from unsafe “drinking water, poor sanitation and malnutrition,” according to Oxford University’s Our World In Data portal. On Monday, DARPA announced it was researching an “implantable or ingestible bioelectronic carrier” that would eliminate the five major bacteria associated with traveler’s diarrhea.

Read More

Closing bacterial genomes from the human gut microbiome using long-read sequencing

Article | February 12, 2020

In our lab, we focus on the impact of the gut microbiome on human health and disease. To evaluate this relationship, it’s important to understand the particular functions that different bacteria have. As bacteria are able to exchange, duplicate, and rearrange their genes in ways that directly affect their phenotypes, complete bacterial genomes assembled directly from human samples are essential to understand the strain variation and potential functions of the bacteria we host. Advances in the microbiome space have allowed for the de novo assembly of microbial genomes directly from metagenomes via short-read sequencing, assembly of reads into contigs, and binning of contigs into putative genome drafts. This is advantageous because it allows us to discover microbes without culturing them, directly from human samples and without reference databases. In the past year, there have been a number of tour de force efforts to broadly characterize the human gut microbiota through the creation of such metagenome-assembled genomes (MAGs)[1–4]. These works have produced hundreds of thousands of microbial genomes that vastly increase our understanding of the human gut. However, challenges in the assembly of short reads has limited our ability to correctly assemble repeated genomic elements and place them into genomic context. Thus, existing MAGs are often fragmented and do not include mobile genetic elements, 16S rRNA sequences, and other elements that are repeated or have high identity within and across bacterial genomes.

Read More

5 Biotech Stocks Winning the Coronavirus Race

Article | April 13, 2020

There are quite a few companies that have found ways to grow their business during the ongoing COVID-19 pandemic. This is especially true for a number of biotechs now working on developing a potential treatment for, or vaccine against, the virus; shares of such companies have largely surged over the past couple of months. Although many of these treatments and vaccines are still have quite a way to go before they're widely available, it's still worth taking some time to look through what's going on in the COVID-19 space right now. Here are five biotech stocks that are leading the way when it comes to addressing COVID-19. Regeneron Pharmaceuticals (NASDAQ:REGN) wasn't among the initial wave of companies to announce a potential COVID-19 drug. However, investor excitement quickly sent shares surging when the company announced that its rheumatoid arthritis drug, Kevzara, could help treat COVID-19 patients.

Read More

Top 10 biotech IPOs in 2019

Article | February 24, 2020

The big question at the start of 2019 was whether the IPO window would stay open for biotech companies, particularly those seeking to pull off ever-larger IPOs at increasingly earlier stages of development. The short answer is yes—kind of. Here’s the long answer: In the words of Renaissance Capital, the IPO market had “a mostly good year.” The total number of deals fell to 159 from 192 the year before, but technology and healthcare companies were standout performers. The latter—which include biotech, medtech and diagnostics companies—led the pack, making up 43% of all IPOs in 2019. By Renaissance’s count, seven companies went public at valuations exceeding $1 billion, up from five the year before

Read More

Spotlight

BioTech Annecto

BioTech Annecto is a social networking organization, whose aim is to bring together entrepreneurs, investors, scientists, attorneys, journalists and other professionals in the biotechnology sector: pharmaceutical, healthcare and biomedical, cosmetics, and environment. Launched February 2009 in Montreal (Quebec, Canada), BioTech Annecto (previously known as BioTech Montreal) is inviting people, one Tuesday every month, from the Montreal biotechnology community to meet at trendy locations around town. Members come from the business world, from public agencies as well as academic institutions. This allows regular communication and exchanges between industry, the public sector and academia.

Events